Establishment of the endocrine variant extractor and its clinical application in identifying a novel GATA3 mutation in HDR syndrome - Summary - MDSpire
Advertisement
Establishment of the endocrine variant extractor and its clinical application in identifying a novel GATA3 mutation in HDR syndrome
To develop a bioinformatics pipeline, the endocrine variant extractor (EVE), for efficient genetic screening in endocrine disorders, particularly focusing on parathyroid and broader metabolic conditions.
Approach:
Pipeline Development: EVE is encapsulated in a Docker container and automated with a Python wrapper, integrating core bioinformatics engines such as BWA-MEM, GATK, and SnpEff for variant filtering and annotation.
Key Findings:
EVE identified the first Korean case of a de novo GATA3 frameshift variant (p.Ala173fs) in a patient with HDR syndrome, which had not been previously reported.
The analysis time was approximately 3 hours, reducing manual data review by over 99.6%.
Interpretation:
EVE streamlines the process of identifying clinically relevant variants from WES data, facilitating the diagnosis of endocrine disorders.
Limitations:
The study does not address the performance of EVE across diverse populations beyond the tested clinical datasets, limiting its generalizability.
Conclusion:
EVE provides a high-efficiency workflow for genetic screening, contributing to the creation of an endocrine variant atlas for improved diagnostics.
